NR3C1 and asthma: In the present study we showed that a p38MAPK inhibitor (SB203580) preferentially restored corticosteroid sensitivity in PBMCs from a subpopulation of severe asthma that were characterized by increased ex-vivo corticosteroid insensitivity, decreased GR nuclear translocation and clinically by a tendency for reduced lung function and higher use of oral corticosteroids.